Dublin City University collaborates with Irish medical device company PBC Biomed

1 min read

Dublin City University (DCU) have collaborated with Irish medical device company PBC Biomed on a new bone fracture treatment, that has recently been awarded ‘Breakthrough Device Designation’ by the FDA.

This new bioadhesive is a biomaterial, which has been engineered to interact with biological systems. In this case, the bioadhesive can help to heal bone fractures. This is achieved by the bioadhesive using phosphoserine, a molecule found in various proteins which, when combined with alpha-tricalcium phosphate powder, generates adhesive biomaterial that can stabilise and repair bone fractures.

Prof Nick Dunne, Executive Director of Biodesign Europe, said: “The collaboration between Dublin City University and PBC Biomed exemplifies the power of interdisciplinary efforts in research and development. The ‘Breakthrough Device’ designation bythe FDA validates the promising trajectory of OsStic®, showcasing Ireland’s capability to lead in cutting-edge medical technologies. This achievement not only highlights the success of the project, but also emphasises the importance of sustained investment in disruptive technologies to foster innovation and elevate Ireland’s global standing in the medical device industry.”

Dr Carolyn Hughes from DCU Invent said: “We congratulate the team at PBC Biomed on achieving this important milestone. This illustrates the ability to accelerate innovation through effective collaboration with our world-class research experts at DCU. The breakthrough offers the potential for life-changing improvement to patients’ lives.”

At present, metal hardware is widely used in treating post-traumatic bone injuries. Although, this hardware has many limitations, meaning it can result in poor healing. Bone plates, screws and pins tend to loosen, necessitating their removal, which can lead to loss of crucial bone material.